Lipocine Inc. (LPCN) AI Stock Analysis

Lipocine Inc. is a clinical-stage biopharmaceutical company focused on advancing treatments for neuroendocrine and metabolic disorders by developing oral delivery solutions for drugs with poor bioavailability. Its pipeline features TLANDO, an oral testosterone replacement therapy. Lipocine is also developing LPCN 1144, an oral bioidentical testosterone prodrug that completed Phase II trials for non-cirrhotic non-alcoholic steatohepatitis, and LPCN 1111, which finished Phase II trials for hypogonadal men. Additional programs include LPCN 1148 for decompensated cirrhosis and LPCN 1154, which targets postpartum depression with an investigational new drug application for a Phase 2 study.

Lipocine has experienced volatile revenue across recent fiscal years. Revenue dropped from $16.1M in FY2021 to $500,000 in FY2022, reported -$2.9M in FY2023, rose to $11.2M in FY2024, and fell 82.3% to $2.0M in FY2025. Gross margin was -334.3% and operating margin was -524.7% in FY2025, resulting in net income of -$9.6M and an EPS of -$1.77. Research and development expense was $8.6M in FY2025. Over the trailing twelve months, revenue was $1.6M, with an operating margin of -1495.1% and EPS of -$1.85. For the latest quarter ended June 30, 2026, quarterly revenue fell 69.5% year-over-year.

As of June 30, 2026, Lipocine held $23.3M in cash and short-term investments, with total assets of $23.8M and shareholders' equity of $21.8M. Its current ratio stood at 11.48. In FY2025, operating cash flow was -$9.8M and free cash flow was -$9.8M. Capital expenditures were $1 in FY2025. The company's share count increased 57.1% over a five-year period.

Lipocine has a market capitalization of $12.9M and an enterprise value of -$5.7M. The stock trades at a price-to-sales multiple of 8.2x, which is higher than the median of 4.1x for its US-listed Healthcare peers. Its price-to-book ratio is 0.8x, and its forward P/E is 5.6x, compared to 17.3x for the peer median. Over the past year, LPCN fell 49.8% and declined 80.6% year-to-date, trailing the S&P 500 (SPY) return of 16.8% over the past year.

Analyst coverage for Lipocine shows 1 Strong Buy and 1 Hold rating, with no Buy, Sell, or Strong Sell recommendations. The mean price target is $5.00, representing a 220.5% premium over the last close of $1.56. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $631,250 and EPS of -$1.54. For the next fiscal year, 2 analysts estimate revenue of $745,000 and EPS of -$1.34. Lipocine beat EPS expectations in 2 of the last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of Lipocine Inc. (LPCN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: LPCN income statement, LPCN balance sheet, LPCN key metrics, LPCN analyst forecast, LPCN chart. See the LPCN stock overview for the latest quote and news.